Biological Therapeutics for Infection-Relating Disorders or Conditions

Abstract

The present invention discloses products and the methods of uses of the products for preventing and treating infectious diseases and the disorders or conditions inducible by harmful antibodies. The harmful antibodies are induced during infection, or vaccination, or use of therapeutic antibodies. The products of the present disclosure comprise immunoglobulin products, scrum or plasma, specific antibodies to viral pathogens.

1 - 36 . (canceled) 
     
     
         37 . A substance or product which interrupts the binding of a harmful antibody to a host cell or tissue, wherein the substance or the product is:
 a) serum or plasma, wherein the serum or plasma is pooled from multiple individuals;   b) an immunoglobulin or an antibody different from the harmful antibody, wherein the immunoglobulin or antibody is formulated as lyophilized, an injectable, or an infusion; or   c) a pathogen-deriving product, a host-deriving product, or a saccharide, wherein the product or saccharide is formulated as lyophilized, an injectable, or an infusion;   wherein the harmful antibody is induced by a pathogen, a vaccine or a passively introduced therapeutic antibody; and wherein the harmful antibody binds to a host cell or tissue and induces infection-relating disorders including autoimmune diseases, infection-relating inflammation, serious adverse reactions of vaccines or therapeutic antibodies, infection-relating tumors, infection-relating allergies, and other infection-relating disorders.   
     
     
         38 . The substance or product of  claim 37 , wherein the pathogen comprises at least one of a virus, a bacteria, a parasite, a fungi, a viroid, or a prion. 
     
     
         39 . The substance or product of  claim 37 , wherein the vaccine comprises an influenza vaccine. 
     
     
         40 . The substance or product of  claim 37 , wherein the serum or plasma is formulated as lyophilized, an injectable, or an infusion. 
     
     
         41 . A vaccine comprising a first pathogen which induces antibodies capable of protecting an infection caused by a second pathogen. 
     
     
         42 . The vaccine of  claim 41 , wherein the first pathogen comprises at least one of a hepatitis A virus (HAV), a hepatitis B virus (HBV), a respiratory syncytial virus (RSV), or a rotavirus. 
     
     
         43 . The vaccine of  claim 41 , wherein the second pathogen comprises an influenza virus. 
     
     
         44 . A method of using a vaccine made of a first pathogen for preventing and treating diseases and conditions relating to an infection caused by a second pathogen, wherein the vaccine is capable of inducing antibodies capable of preventing an infection caused by a second pathogen; and wherein the vaccine is capable of inducing antibodies capable of interrupting, competing or neutralizing harmful antibodies induced by the second pathogen. 
     
     
         45 . The method of  claim 44 , wherein the second pathogen comprises an influenza virus.